Get the Stockscreener App
6.10
1.93%
-0.12
After Hours:
6.65
0.55
+9.02%
Apollomics Inc stock is traded at $6.10, with a volume of 4,853.
It is down -1.93% in the last 24 hours and down -5.13% over the past month.
Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.
See More
Previous Close:
$6.22
Open:
$6.69
24h Volume:
4,853
Relative Volume:
0.20
Market Cap:
$6.71M
Revenue:
-
Net Income/Loss:
$-57.11M
P/E Ratio:
-0.4067
EPS:
-15
Net Cash Flow:
$-34.82M
1W Performance:
-13.84%
1M Performance:
-5.13%
6M Performance:
-31.46%
1Y Performance:
-80.12%
1-Day Range:
$6.10
$6.77
1-Week Range:
$5.98
$7.14
52-Week Range:
$4.4701
$35.98
Apollomics Inc Stock (APLM) Company Profile
Compare APLM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
APLM
Apollomics Inc
|
6.10 | 7.81M | 0 | -57.11M | -34.82M | -15.00 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Apollomics Inc Stock (APLM) Latest News
Short Interest in Apollomics, Inc. (NASDAQ:APLMW) Increases By 75.8% - Defense World
How the (APLM) price action is used to our Advantage - news.stocktradersdaily.com
Apollomics (APLM) Trading Halted Due to Volatility | APLM Stock News - GuruFocus
Apollomics (APLM) Stock Trading Resumes | APLM Stock News - GuruFocus
(APLM) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
Short Interest in Apollomics, Inc. (NASDAQ:APLMW) Decreases By 44.4% - Defense World
APLM stock touches 52-week low at $4.71 amid sharp annual decline By Investing.com - Investing.com South Africa
APLM stock touches 52-week low at $4.71 amid sharp annual decline - Investing.com Canada
(APLM) Investment Analysis - news.stocktradersdaily.com
APLM stock touches 52-week low at $6 amid market challenges - Investing.com Australia
Apollomics Reports Full Year 2024 Financial Results and Highlights Clinical Updates and Business Progress - The Manila Times
Apollomics Achieves Major Clinical Win: 43% Response Rate Plus New $10M Partnership Deal Extends Runway - Stock Titan
Apollomics and LaunXP ink $50 M deal for NSCLC treatment in Asia - BioSpectrum Asia
Apollomics and LaunXP agree on NSCLC treatment in Asia - Yahoo
Apollomics, Inc. (NASDAQ:APLMW) Sees Significant Growth in Short Interest - Defense World
Apollomics, LaunXP enter development, commercial agreement for Vebreltinib - MSN
Apollomics Signs Exclusive Development, Commercialization Deal for Vebreltinib in Asia - MarketScreener
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Apollomics and LaunXP Announce Development and Commercialization Agreement for Vebreltinib - GlobeNewswire
$60M Deal: Apollomics' Lung Cancer Drug Breakthrough Expands Across Asia - Stock Titan
Better Artificial Intelligence Stock: SoundHound AI vs. C3.ai - The Globe and Mail
Apollomics Inc. and LaunXP International Co., Ltd., Affiliate of LaunXP Biomedical Co., Ltd. Announce Development and Commercialization Agreement for Vebreltinib - marketscreener.com
(APLM) Long Term Investment Analysis - news.stocktradersdaily.com
Why Coinbase (COIN) Stock Is Trading Up Today - The Globe and Mail
Apollomics, Inc. (NASDAQ:APLMW) Short Interest Update - Defense World
These Were the 2 Top-Performing Stocks in the S&P 500 in February 2025 - The Globe and Mail
(APLM) Trading Advice - Stock Traders Daily
Apollomics, Inc. (NASDAQ:APLMW) Sees Large Decrease in Short Interest - Defense World
APLM Stock Hits 52-Week Low at $6.2 Amid Steep Yearly Decline - Investing.com Australia
APLM Stock Hits 52-Week Low at $6.2 Amid Steep Yearly Decline By Investing.com - Investing.com South Africa
APLM stock touches 52-week low at $6.38 amid market challenges - MSN
APLM stock touches 52-week low at $6.38 amid market challenges By Investing.com - Investing.com South Africa
Objective long/short (APLM) Report - Stock Traders Daily
Apollomics, Inc. (NASDAQ:APLMW) Sees Significant Decrease in Short Interest - Defense World
Apollomics phase 3 trial in China shows no benefit - Investing.com India
Biotech fails trials for its leukemia drug - Silicon Valley Business Journal
Apollomics Shares Down in Premarket After Leukemia Drug Misses Phase-3 Targets - MarketWatch
Apollomics Announces Top-line Results for Phase 3 Bridging - GlobeNewswire
Apollomics' Cancer Drug Disappoints in Phase 3 Trial with Lower Survival Rates, Program Terminated - StockTitan
Apollomics, after giving up on GlycoMimetics' leukemia therapy, posts drug's latest phase 3 fail - Fierce Biotech
Apollomics Meets Nasdaq Compliance On Bid Price Requirement - Nasdaq
APLM Stock Hits 52-Week Low at $7.51 Amid Market Challenges - Investing.com Australia
APLM Stock Hits 52-Week Low at $7.51 Amid Market Challenges By Investing.com - Investing.com South Africa
Apollomics Regains Compliance with Nasdaq’s Minimum Bid Price Requirement - GlobeNewswire
Apollomics Secures Nasdaq Listing Status After Meeting Crucial Price Requirements - StockTitan
When the Price of (APLM) Talks, People Listen - Stock Traders Daily
Apollomics Inc trading halted, news pending - MSN
APLM Stock Plummets to 52-Week Low, Hits $8.01 Amid Market Turbulence - Investing.com India
APLM Stock Plummets to 52-Week Low, Hits $8.01 Amid Market Turbulence By Investing.com - Investing.com South Africa
Apollomics Inc Stock (APLM) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.89%
3.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):